×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VKTX – viking therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VKTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
07:00 am
vktx
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Low
Report
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
1/11
06:40 am
vktx
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale [Yahoo! Finance]
Low
Report
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale [Yahoo! Finance]
1/10
07:02 pm
vktx
Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? [Yahoo! Finance]
Low
Report
Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? [Yahoo! Finance]
1/9
07:03 pm
vktx
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug [Yahoo! Finance]
Low
Report
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug [Yahoo! Finance]
1/8
07:59 pm
vktx
Lightning Round: QXO is a buy, says Jim Cramer [CNBC]
Low
Report
Lightning Round: QXO is a buy, says Jim Cramer [CNBC]
1/8
07:27 am
vktx
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity [Yahoo! Finance]
Low
Report
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity [Yahoo! Finance]
1/8
07:00 am
vktx
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
Low
Report
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
1/7
07:13 am
vktx
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/22/2025
04:05 pm
vktx
viking therapeutics, inc.
MISS
Report
8.0%
viking therapeutics, inc.
4/23/2025
04:05 pm
vktx
viking therapeutics, inc.
MISS
Report
-1.1%
viking therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/5
08:32 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: ZANTE GREG
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: ZANTE GREG
1/5
08:31 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Mancini Marianna
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Mancini Marianna
1/5
08:28 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Lian Brian
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Lian Brian
1/5
08:27 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: SINGLETON J MATTHEW
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: SINGLETON J MATTHEW
1/5
08:26 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: MACARTNEY LAWSON
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: MACARTNEY LAWSON
1/5
08:26 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: FOEHR MATTHEW W
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: FOEHR MATTHEW W
1/5
08:26 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Rowland Charles A Jr
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Rowland Charles A Jr
1/5
08:25 pm
vktx
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Rouan Sarah Kathryn
Low
Report
Form 4 Viking Therapeutics, For: Jan 02 Filed by: Rouan Sarah Kathryn
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
19.0%
3/19 Viking Therapeutics Inc (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at William Blair. 8.1%
5/4 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.2%
12/21 Viking Therapeutics Inc (NASDAQ: VKTX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.8%
4/3 Form 4 Viking Therapeutics, For: Mar 31 Filed by: MORNEAU MICHAEL 5.4%
11/12 Viking Therapeutics to Participate in Upcoming Investor Conferences 4.9%
10/31 Form 4 Viking Therapeutics, For: Oct 31 Filed by: MORNEAU MICHAEL 4.7%
3/17 Form 8-K Viking Therapeutics, For: Mar 17 3.7%
7/15 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at Citigroup Inc. They set an "outperform" rating on the stock. 3.5%
8/6 Viking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript [The Motley Fool] 2.6%
3/19 Viking Therapeutics Inc (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at William Blair. 8.1%
5/4 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.2%
12/21 Viking Therapeutics Inc (NASDAQ: VKTX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.8%
4/3 Form 4 Viking Therapeutics, For: Mar 31 Filed by: MORNEAU MICHAEL 5.4%
11/12 Viking Therapeutics to Participate in Upcoming Investor Conferences 4.9%
10/31 Form 4 Viking Therapeutics, For: Oct 31 Filed by: MORNEAU MICHAEL 4.7%
3/17 Form 8-K Viking Therapeutics, For: Mar 17 3.7%
7/15 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at Citigroup Inc. They set an "outperform" rating on the stock. 3.5%
8/6 Viking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript [The Motley Fool] 2.6%
TOP News Decliners
11/19
Viking launches mid-stage study of VK2809 in NASH; shares up 7% premarket [Seeking Alpha]
-15.5%
3/21 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -9.0%
1/3 Form 4 Viking Therapeutics, For: Jan 02 Filed by: SINGLETON J MATTHEW -9.0%
2/26 Form 10-K Viking Therapeutics, For: Dec 31 -8.7%
5/28 Viking Therapeutics to Participate in Upcoming Investor Conferences -8.2%
5/1 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $9.00 price target on the stock. -7.6%
8/11 Is Viking Therapeutics a Buy? [The Motley Fool] -7.3%
8/1 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.090 ActVsEst (0.020) - Miss -6.6%
5/7 3 Top Biotech Stocks to Buy in May [The Motley Fool] -6.2%
4/14 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.8%
3/21 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -9.0%
1/3 Form 4 Viking Therapeutics, For: Jan 02 Filed by: SINGLETON J MATTHEW -9.0%
2/26 Form 10-K Viking Therapeutics, For: Dec 31 -8.7%
5/28 Viking Therapeutics to Participate in Upcoming Investor Conferences -8.2%
5/1 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $9.00 price target on the stock. -7.6%
8/11 Is Viking Therapeutics a Buy? [The Motley Fool] -7.3%
8/1 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.090 ActVsEst (0.020) - Miss -6.6%
5/7 3 Top Biotech Stocks to Buy in May [The Motley Fool] -6.2%
4/14 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: